CT45 Targeted CAR-T Therapy for Ovarian Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Resistance to chemotherapy is a major factor in the poor survival rate of women with ovarian cancers, particularly high-grade serous ovarian carcinoma (HGSOC), which accounts for 70% of all ovarian cancers and 60% of deaths related to the disease.
Innovation Solution
The development of methods for treating ovarian cancer based on specific antigen expression, specifically using chimeric antigen receptors (CAR) or T cell receptors (TCR) that bind to the CT45 polypeptide, in combination with immunotherapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat ovarian cancer, then cancer cells are killed, but resistance develops leading to poor survival rates
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach from conventional chemotherapy to targeted immunotherapy using CAR-T cells. This involves changing the mechanism of action from non-specific chemical killing to specific antigen recognition and immune-mediated destruction, thereby overcoming chemotherapy resistance while maintaining treatment efficacy
Solution Approach 2:
The patent introduces CAR-T cells as an intermediary between the patient's immune system and the cancer cells. These engineered T cells serve as mediators that specifically recognize CT45 antigen on ovarian cancer cells and deliver targeted destruction, bypassing the resistance mechanisms that develop against direct chemotherapy
2Reliability
If trial and error approach is used to select treatment, then some patients may respond, but the aggressive nature of ovarian cancer leaves little room for error
Solution Approach 1:
The patent performs preliminary action by pre-engineering T cells with specific CAR receptors targeted to CT45 antigen before administration. This advance preparation ensures that the therapeutic cells are ready to immediately recognize and attack cancer cells upon infusion, eliminating the need for trial and error treatment selection and reducing time loss
Solution Approach 2:
The patent incorporates feedback mechanisms through the specific antigen recognition system. The CAR-T cells are designed to continuously monitor for CT45 antigen expression on cancer cells, providing real-time feedback that guides their attack. This targeted feedback system ensures reliable treatment response without requiring multiple trial treatments
3Reliability
If personalized medicine approaches are implemented, then treatment efficacy is improved, but complexity of treatment selection increases
Solution Approach 1:
The patent applies local quality by engineering T cells with site-specific customization - each patient's T cells are modified to express CAR receptors that specifically recognize their tumor's CT45 antigen. This localized personalization at the cellular level achieves high treatment efficacy while maintaining a relatively simple overall treatment framework compared to comprehensive personalized medicine approaches
Data Source
AI summary
The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.